Plus Therapeutics (NASDAQ:PSTV) Posts Earnings Results, Misses Expectations By $0.43 EPS

Plus Therapeutics (NASDAQ:PSTV) issued its quarterly earnings data on Friday. The company reported ($1.31) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.88) by ($0.43), FiscalAI reports. Plus Therapeutics had a negative return on equity of 198.48% and a negative net margin of 230.24%.The business had revenue of $0.41 million for the quarter, compared to analyst estimates of $1.11 million.

Plus Therapeutics Stock Performance

Shares of Plus Therapeutics stock remained flat at $3.70 on Friday. 62,111 shares of the stock traded hands, compared to its average volume of 116,506. Plus Therapeutics has a twelve month low of $2.90 and a twelve month high of $23.42. The stock has a market cap of $25.47 million, a P/E ratio of -1.61 and a beta of 1.40. The business has a 50 day simple moving average of $4.12 and a 200-day simple moving average of $5.44.

Wall Street Analyst Weigh In

Several brokerages have weighed in on PSTV. Ascendiant Capital Markets cut their target price on Plus Therapeutics from $65.00 to $57.00 and set a “buy” rating on the stock in a research note on Monday, June 8th. Weiss Ratings reissued a “sell (e+)” rating on shares of Plus Therapeutics in a research note on Friday, July 17th. Four analysts have rated the stock with a Buy rating, two have given a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, Plus Therapeutics presently has an average rating of “Hold” and an average target price of $56.40.

Institutional Investors Weigh In On Plus Therapeutics

A number of institutional investors have recently added to or reduced their stakes in PSTV. Jane Street Group LLC bought a new stake in shares of Plus Therapeutics in the 2nd quarter worth $41,000. Susquehanna International Group LLP bought a new position in Plus Therapeutics during the third quarter valued at about $46,000. Scientech Research LLC acquired a new position in Plus Therapeutics during the third quarter worth about $100,000. XTX Topco Ltd acquired a new position in Plus Therapeutics during the fourth quarter worth about $127,000. Finally, State Street Corp raised its position in Plus Therapeutics by 37.1% in the fourth quarter. State Street Corp now owns 468,893 shares of the company’s stock worth $240,000 after acquiring an additional 127,000 shares in the last quarter. 3.28% of the stock is currently owned by institutional investors and hedge funds.

About Plus Therapeutics

Plus Therapeutics is a clinical‐stage biopharmaceutical company specializing in the development of targeted radiotherapeutics for oncology. Its platform technologies leverage nanoliposomes and microspheres to deliver therapeutic radioisotopes directly to tumor sites. The company’s lead candidate, 90Y-HP-DO3A, is in Phase 2 development for recurrent high-grade gliomas, while its rhenium-based nanoliposome program is under investigation for diffuse intrinsic pontine glioma and brain metastases.

The pipeline also includes investigational treatments for bone metastases, malignant pleural effusions and other hard-to-treat solid tumors.